

Monthly News – May 2013

Department of Psychiatry

May 20, 2013 Volume 7, Number 5

APA Annual Meeting May 18-22:

The 166th Annual Meeting of the American Psychiatric Association was held in San Francisco from May 18th-22nd.

Presentations from UH Department of Psychiatry included:

Courses:

Psychiatrist as Expert Witness
Phillip Resnick, M.D.
Saturday, May 18, 2013

Risk Assessment for Violence
Phillip Resnick, M.D.
Monday, May 20, 2013

The Detection of Malingered Mental Illness
Phillip Resnick, M.D.
Monday, May 20, 2013

The Expert Witness in Psychiatric Malpractice Cases
Phillip Resnick, M.D.
Tuesday, May 21, 2013

New Research – Scientific Program

The Safety and Efficacy of Quetiapine-XR Monotherapy or Adjunctive Therapy to Mood Stabilizer in Bipolar Depression with Generalized Anxiety Disorder
Lead Author: **Keming Gao, M.D., Ph.D.**
Co-Author(s): **Keming Gao, MD, PhD, Jun Chen MD, PhD, David**

E. Kemp, MD, MS, Carla Conroy, BA, Philip Chan, MS, Mary Beth Serrano, MA, Renee Slembariski, BA, Stephen J. Ganocy PhD, Joseph R. Calabrese MD

Similarity and Difference Between Suicidality and Number of Comorbidities and Depression/Anxiety Severity in Patients with MDD or Bipolar Disorders
Lead Author: **Keming Gao, M.D., Ph.D.** Co-Author(s): Zuowei Wang, MD, PhD, Jun Chen MD, PhD, **Philip K. Chan, MS, Carla M. Conroy, BA, Mary Beth Serrano, MA, David E. Kemp, MD, Stephen J. Ganocy, PhD, Joseph R. Calabrese, MD.**

Efficacy and Safety of Low and High Dose Catiprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Lead Author: **Joseph R. Calabrese, M.D.**

A Post Hoc Analysis of Efficacy and Tolerability of Lurasidone Adjunctive to Either Lithium or Valproate for the Treatment of Bipolar I Depression
Lead Author: **Joseph R. Calabrese, M.D.**

Judicial Bypass for Parental Consent for Abortion: Jane Doe Evaluations and Outcomes
Lead Author: **Susan Hatters-Friedman, M.D.**
Co-Author(s): Todd Hendrix, PhD, Abhishek Jain, MD, Jessica Haberman, MA

*“And Then I Woke Up in Jail”:
Amnesia Claims in Court-Ordered Evaluations*
Lead Author: **Susan Hatters-Friedman, M.D.**
Co-Author(s): **John Preston Shand**; Renee M. Sorrentino, MD; George W. Schmedlen, PhD, JD

Postpartum Depression and Anxiety Among Mothers of Infants in the Neonatal Intensive Care Unit
Lead Author: **Susan Hatters-Friedman, M.D.** Co-Author(s): Amie Rebecca Ballard, MD, Susan Hatters Friedman, MD, and **John Preston Shand.**

Complementary Treatment for Anxiety and Stress:

The Connor Integrative Medicine Network is now offering Acupuncture Treatment for Anxiety and Stress.

In addition to treating an array of physical conditions and symptoms, acupuncture may successfully treat anxiety and stress by calming the nervous system, decreasing heart rate and promoting relaxation. Studies have shown that many commonly used acupuncture points (or areas of needle insertion) are located in parts of the body that are highly abundant in nerve fibers, nerve bundles and mast cells. Needles inserted into these areas of

the body communicate with the peripheral and central nervous system, sending signals to the brain to release and regulate mood enhancing and pain inhibiting hormones, such as dopamine and cortisol.

Through this mechanism of communicating with the nervous system, acupuncture naturally helps bring the body into state of relaxation and homeostasis, making it highly effective for treating anxiety, stress, and emotional imbalances. Most patients leave their acupuncture treatment with an elevated sense of well being and a relaxed body and mind. With each acupuncture session this sense of wellbeing is built upon, “resetting” the body and mind to a state of harmony. Acupuncture can be used in conjunction with Western Medicine and might be a good treatment option for some patients that are looking for more balance in their emotional life.

Please feel free to contact **Dr. Francoise Adan** with any questions regarding acupuncture as a complementary treatment for anxiety and stress.

To schedule appointments in one of four locations, please call 216 285-4070. Individual and Community Acupuncture is available.

Congratulations:

To: All of the UH psychiatry residents and the child and adolescent psychiatry fellow who presented oral platforms and posters at the annual CL Society Meeting on May 1st: An'Drea Taylor, Ben Cheng, Shree Sarathy, Mauran Sivananthan, Mariya Borodyanskaya, Elise Bonder, and Smitha Battula.

PGY-2 psychiatry resident, **Elise Bonder, MD**, won the PARSA award for best oral platform presentation. Dr. Bonder's

presentation was: "Evaluation of 1st break psychosis and Delirium."

To: **Latoya Paul** of the UH Richmond Geriatric Psychiatry Unit obtained her RN license on March 27 2013.

To: **Tiffany Thomas M.D.**, and her husband Matt Lakia on the birth of their daughter, Savannah Rose, born May 1st at 1:48p.m., 8 lbs 9 oz and 21 inches.



General News:

Maryland Governor Martin O'Malley recently signed [Maryland House Bill 690](#), establishing the **Virginia I. Jones Alzheimer's Disease and Related Disorders Council**. The Council is named in honor of **Dr. Pythias Jones'** mother, Virginia I. Jones.

Child and Adolescent Psychologist, **Dr. Aaron Ellington** was interviewed on WKYC Channel 3 to provide tips on how to handle college graduates moving back in with their parents on May 7th.

Dr. Ellington was also interviewed on May 8th and May 20th regarding the safe return of Amanda Berry, Gina DeJesus and Michelle Knight and how teens may deal with trauma.

Grand Rounds:

May 24th:
Speaker: Priti Purushothaman, MD
Topic: What's New with Stimulants?

May 31st:
Speaker: Smitha Battula, MD
Topic: Pediatric Insomnia

June 7th:
DEPARTMENT MEETING
With Thomas Zenty

June 14th:
Speaker: Karl Mobbs, MD
Topic: Forensic Psychiatry and the Law: Beyond the DSM V

June 21st:
Speaker: Cheryl Wills, M.D.
Topic: FMLA and Disability Assessments

June 28th:
****Irving and Ellen Rothchild Lecture***
Speaker: Stephen J. Ferrando, M.D.
Topic: Diagnosis and Treatment of HIV –Associated Neurocognitive Disorders

****Reception immediately following the lecture in the Mayer-Haber Conference Room 13-113***

Presentations and Publications:

Wang, A.R., Pagano, M. E., Scur, M. D., & Delos-Reyes, C. M. (2013, April). Associations between anxiety disorders and substance use disorders in substance-dependent adolescents. Poster presentation at the 43rd annual meeting of ASAM, Chicago, IL.

Delos Reyes, C. M., Svala, K., Singh, N., Scur, M., & Pagano, M. (2013, March). *Smoking Cessation and Adolescent Treatment Outcomes*. Poster presentation at the 11th All-Ohio Institute on Community Psychiatry, Beachwood, OH. **First place research competition winner.**

Veta, P.S., **Pagano, M.E.**, & Lee, M.T. (2013, April). *God-consciousness and youth substance abuse: influences on chemical dependency treatment?* Poster presentation at CWRU SOURCE Symposium annual meeting, Cleveland, OH.

Phillip Resnick, M.D. presented a workshop on Risk Assessment for Violence April 26, 2013 at the Battleboro Retreat, Battleboro, Vermont.

Stephen Noffsinger, M.D. presented a seminar on Competence to Stand Trial and the Insanity Defense to the Stark County Bar Association on May 10 in Canton, Ohio.

Dr. Resnick and Dr. Noffsinger both presented at the Cuyahoga County Prosecutor's Office Spring Conference in Cleveland on May 16. Dr. Resnick presented on the Insanity Defense and Diminished Capacity. Dr. Noffsinger presented a Primer on Competency to Stand Trial and Insanity Acquittee Step-Down and Release.

Sajatovic M, Levin J, Ramirez L, Hahn D, Tatsuoka C, Seifi N. A prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. Poster Presentation. 14th International Congress on Schizophrenia Research. Orlando, FL. April 25, 2013.

Dr. Philipp Dines will present at the Clinical Symposium on "Nonpharmacologic Management of Dementia" at the National PACE Summer Conference at the Renaissance Hotel in Cleveland, Ohio on Saturday, June 8th.

Research:

The **Discovery and Wellness Center for Children at University Hospitals Case Medical Center** is a pediatric research center that offers several research based treatment programs for children and adolescents who suffer emotional and behavioral difficulties. Every year nearly 5

million children suffer from a psychiatric illness that significantly interferes with their daily living. Anxiety, ADHD, autism, depression and other mood disorders are just a few. Children and teenagers with emotional or behavioral disorders can be at a higher risk for other serious problems. Response to treatment may vary, but when treated properly, many children can be like other kids. Eligibility varies for each treatment program. Treatment can include evaluations from a doctor who specializes in pediatric mental health, laboratory tests, and study medication at no cost. To learn more about the program, please call the confidential intake line at 216-844-3922 or send an email to DWCC@Uhhospitals.org.

OPT-BD Research Study

Do you see any patients who are **60 years old or older with type I Bipolar Disorder** and are currently **sub-optimally responsive** to their prescribed BD treatments?

To participate, individuals must:

- 1.) Have Type I Bipolar Disorder
- 2.) Be age 60 or older
- 3.) Have sub-optimal response to current psychotropic management including:
 - a. Behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence
 - b. Diminished ability to take care of basic personal needs in their place of residence due to symptoms of BD

To participate, individuals may NOT have:

- 1.) History of intolerance or resistance to asenapine
- 2.) Clinical diagnosis of dementia or Mini-mental state (MMSE) < 24
- 3.) History of TIA, stroke or MI within the past 12 months
- 4.) Rapid cycling BD defined as 4 or more discrete mood episodes within the previous 12 months.

Participants will receive 12 weeks of open-label asenapine. Each study subject will serve as their own baseline control and mood symptoms will be assessed using standardized measures during the 12 weeks of asenapine therapy. The primary outcome is change from baseline in bipolar mood symptom scores (mania and depression). Secondary outcomes include functional and general health status, global psychopathology, side effects, and extrapyramidal symptoms.

For more information or to refer a patient contact Edna Fuentes-Casiano at 216-844-2104 or Effectiveness.Research@UHHospitals.org

CAE RCT Study

Do you have any patients who have Bipolar Disorder and have trouble taking all of their bipolar medication?

To participate, individuals must:

1. Have type I or type II bipolar disorder diagnosis for at least 2 years;
2. Have received treatment with at least one evidence-based medication to stabilize mood for at least six months (lithium, anticonvulsant, or antipsychotic mood stabilizer);
3. Be at least 20% or more non-adherent with current BD medication treatment (i.e. lithium, anticonvulsant, or antipsychotic mood stabilizer);

To participate, individuals may NOT:

1. Be children under the age of 18

This is a randomized, controlled trial (RCT) of the **Customized Adherence Enhancement (CAE) psychosocial intervention** (created by Martha Sajatovic MD and Jennifer Levin PhD) vs. broadly-directed, non-individualized education (EDU) in **poorly adherent individuals with bipolar disorder (BD)**. The study is

primarily interested in testing whether a (CAE) intervention that addresses the specific reasons for non-adherence among high-risk patients with BD improves treatment adherence and bipolar disorder symptoms compared to EDU. CAE is intended to be a brief adjunct to standard mental health treatment. The proposed project has the potential to greatly advance the care of BD patients who are at greatest risk for poor health outcomes, with findings expected to be generalizable across a variety of treatment settings. *All individuals will continue to receive treatment as usual with their regular provider(s).*

For more information or to refer a patient contact Megan Brawley at 216-844-2835 or Effectiveness.Research@UHHospitals.org

Double-Blind, Placebo-Controlled Trial of Pioglitazone for Insulin-Resistant Bipolar Depression

Principal Investigator: David Kemp, MD

Gender & Age: Women & Men, ages 18 & older

Diagnosis: Bipolar Illness (type I, II, or NOS), currently depressed

Medications: Patients will be randomized to either pioglitazone or placebo, in addition to adjunctive anti-manic drug

Study Details: Up to 16 weeks, patients will be seen every week for the first 4 weeks and every two weeks for the remaining month.

Contact: Tim Warneka at 216-844-2863 or via email at:

Timothy.Warneka@uhhospitals.org

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects (TAK-375SL_201)

Principal Investigator: Keming Gao, MD, PhD

Gender & Age: Women & Men, ages 18 - 75

Diagnosis: Bipolar I Disorder, currently depressed

Medications: Lithium and/or one other mood stabilizer (lamotrigine or valproic acid) and/or one atypical antipsychotic (risperidone or olanzapine or aripiprazole or ziprasidone). Subjects may be on one, two or three medications but no more than one from each group. Each subject will be randomized to either TAK -375SL tablet 0.1 mg once daily, TAK-375SL tablet 0.4 mg once daily, TAK-375SL tablet 0.8 mg once daily or placebo once daily.

Study Details: Up to 13 weeks long, visits are once a week for the first month and then bi weekly for an additional month.

Contact: Carla Conroy at 216-844-2871 or via email at:

Carla.Conroy@UHHospitals.org

11th Annual NAMIWalks Greater Cleveland!

When: **Saturday September 7, 2013** Where: Voinovich Park, Cleveland

For more information contact: Bridget Murphy
Special Events Coordinator
216.875.0266

bmurphy@namicleveland.org

Contact:

Published by University Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT ISSUE:

Friday, 06/14/2013

CONTACT: Kate Kilbane

Phone: 216-844-3658

kate.kilbane@uhhospitals.org

Save the Date: